State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Zika virus (ZIKV) is an emerging pathogen associated with neurological complications, such as Guillain–Barré syndrome in adults and microcephaly in fetuses and newborns. This mosquito-borne flavivirus causes important social and sanitary problems owing to its rapid dissemination. However, the development of antivirals against ZIKV is lagging. Although various strategies have been used to study anti-ZIKV agents, approved drugs or vaccines for the treatment (or prevention) of ZIKV infections are currently unavailable. Repurposing clinically approved drugs could be an effective approach to quickly respond to an emergency outbreak of ZIKV infections. The well-established safety profiles and optimal dosage of these clinically approved drugs could provide an economical, safe, and efficacious approach to address ZIKV infections. This review focuses on the recent research and development of agents against ZIKV infection by repurposing clinical drugs. Their characteristics, targets, and potential use in anti-ZIKV therapy are presented. This review provides an update and some successful strategies in the search for anti-ZIKV agents are given.
VM Cao-Lormeau, A Blake, S Mons, S Lastère, C Roche, J Vanhomwegen, T Dub, L Baudouin, A Teissier, P Larre, AL Vial, C Decam, V Choumet, SK Halstead, HJ Willison, L Musset, JC Manuguerra, P Despres, E Fournier, HP Mallet, D Musso, A Fontanet, J Neil, F Ghawché. Guillain–Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016; 387(10027): 1531–1539 https://doi.org/10.1016/S0140-6736(16)00562-6
pmid: 26948433
3
GM Blohm, JA Lednicky, M Márquez, SK White, JC Loeb, CA Pacheco, DJ Nolan, T Paisie, M Salemi, AJ Rodríguez-Morales, J Glenn Morris Jr, JRC Pulliam, AE Paniz-Mondolfi. Evidence for mother-to-child transmission of Zika virus through breast milk. Clin Infect Dis 2018; 66(7): 1120–1121 https://doi.org/10.1093/cid/cix968
pmid: 29300859
4
DL Heymann, A Hodgson, AA Sall, DO Freedman, JE Staples, F Althabe, K Baruah, G Mahmud, N Kandun, PF Vasconcelos, S Bino, KU Menon. Zika virus and microcephaly: why is this situation a PHEIC? Lancet 2016; 387(10020): 719–721 https://doi.org/10.1016/S0140-6736(16)00320-2
pmid: 26876373
5
AD Haddow, AJ Schuh, CY Yasuda, MR Kasper, V Heang, R Huy, H Guzman, RB Tesh, SC Weaver. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl Trop Dis 2012; 6(2): e1477 https://doi.org/10.1371/journal.pntd.0001477
pmid: 22389730
E Mastrangelo, M Milani, M Bollati, B Selisko, F Peyrane, V Pandini, G Sorrentino, B Canard, PV Konarev, DI Svergun, X de Lamballerie, B Coutard, AA Khromykh, M Bolognesi. Crystal structure and activity of Kunjin virus NS3 helicase; protease and helicase domain assembly in the full length NS3 protein. J Mol Biol 2007; 372(2): 444–455 https://doi.org/10.1016/j.jmb.2007.06.055
pmid: 17658551
9
J Lei, G Hansen, C Nitsche, CD Klein, L Zhang, R Hilgenfeld. Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Science 2016; 353(6298): 503–505 https://doi.org/10.1126/science.aag2419
pmid: 27386922
10
B Zhao, G Yi, F Du, YC Chuang, RC Vaughan, B Sankaran, CC Kao, P Li. Structure and function of the Zika virus full-length NS5 protein. Nat Commun 2017; 8(1): 14762 https://doi.org/10.1038/ncomms14762
pmid: 28345656
11
WW Phoo, Y Li, Z Zhang, MY Lee, YR Loh, YB Tan, EY Ng, J Lescar, C Kang, D Luo. Structure of the NS2B-NS3 protease from Zika virus after self-cleavage. Nat Commun 2016; 7(1): 13410 https://doi.org/10.1038/ncomms13410
pmid: 27845325
12
M Onorati, Z Li, F Liu, AMM Sousa, N Nakagawa, M Li, MT Dell’Anno, FO Gulden, S Pochareddy, ATN Tebbenkamp, W Han, M Pletikos, T Gao, Y Zhu, C Bichsel, L Varela, K Szigeti-Buck, S Lisgo, Y Zhang, A Testen, XB Gao, J Mlakar, M Popovic, M Flamand, SM Strittmatter, LK Kaczmarek, ES Anton, TL Horvath, BD Lindenbach, N Sestan. Zika virus disrupts phospho-TBK1 localization and mitosis in human neuroepithelial stem cells and radial glia. Cell Rep 2016; 16(10): 2576–2592 https://doi.org/10.1016/j.celrep.2016.08.038
pmid: 27568284
SA Shiryaev, C Farhy, A Pinto, CT Huang, N Simonetti, A Elong Ngono, A Dewing, S Shresta, AB Pinkerton, P Cieplak, AY Strongin, AV Terskikh. Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists. Antiviral Res 2017; 143: 218–229 https://doi.org/10.1016/j.antiviral.2017.04.015
pmid: 28461069
15
AA Elfiky, WM Elshemey. Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds. J Med Virol 2018; 90(1): 13–18 https://doi.org/10.1002/jmv.24934
pmid: 28922464
16
G Gadea, S Bos, P Krejbich-Trotot, E Clain, W Viranaicken, C El-Kalamouni, P Mavingui, P Desprès. A robust method for the rapid generation of recombinant Zika virus expressing the GFP reporter gene. Virology 2016; 497: 157–162 https://doi.org/10.1016/j.virol.2016.07.015
pmid: 27471954
NJ Barrows, RK Campos, ST Powell, KR Prasanth, G Schott-Lerner, R Soto-Acosta, G Galarza-Muñoz, EL McGrath, R Urrabaz-Garza, J Gao, P Wu, R Menon, G Saade, I Fernandez-Salas, SL Rossi, N Vasilakis, A Routh, SS Bradrick, MA Garcia-Blanco. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe 2016; 20(2): 259–270 https://doi.org/10.1016/j.chom.2016.07.004
pmid: 27476412
19
M Xu, EM Lee, Z Wen, Y Cheng, WK Huang, X Qian, J Tcw, J Kouznetsova, SC Ogden, C Hammack, F Jacob, HN Nguyen, M Itkin, C Hanna, P Shinn, C Allen, SG Michael, A Simeonov, W Huang, KM Christian, A Goate, KJ Brennand, R Huang, M Xia, GL Ming, W Zheng, H Song, H Tang. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med 2016; 22(10): 1101–1107 https://doi.org/10.1038/nm.4184
pmid: 27571349
20
A Wilder-Smith, K Vannice, A Durbin, J Hombach, SJ Thomas, I Thevarjan, CP Simmons. Zika vaccines and therapeutics: landscape analysis and challenges ahead. BMC Med 2018; 16(1): 84 https://doi.org/10.1186/s12916-018-1067-x
pmid: 29871628
Y Han, T Mesplède. Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update. Expert Opin Investig Drugs 2018; 27(12): 951–962 https://doi.org/10.1080/13543784.2018.1548609
pmid: 30430882
M Schlitzer. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem 2007; 2(7): 944–986 https://doi.org/10.1002/cmdc.200600240
pmid: 17530725
28
R Delvecchio, LM Higa, P Pezzuto, AL Valadão, PP Garcez, FL Monteiro, EC Loiola, AA Dias, FJ Silva, MT Aliota, EA Caine, JE Osorio, M Bellio, DH O’Connor, S Rehen, RS de Aguiar, A Savarino, L Campanati, A Tanuri. Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses 2016; 8(12): E322 https://doi.org/10.3390/v8120322
pmid: 27916837
29
CQ Sacramento, GR de Melo, CS de Freitas, N Rocha, LV Hoelz, M Miranda, N Fintelman-Rodrigues, A Marttorelli, AC Ferreira, G Barbosa-Lima, JL Abrantes, YR Vieira, MM Bastos, E de Mello Volotão, EP Nunes, DA Tschoeke, L Leomil, EC Loiola, P Trindade, SK Rehen, FA Bozza, PT Bozza, N Boechat, FL Thompson, AM de Filippis, K Brüning, TM Souza. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep 2017; 7(1): 40920 https://doi.org/10.1038/srep40920
pmid: 28098253
30
Z Li, M Brecher, YQ Deng, J Zhang, S Sakamuru, B Liu, R Huang, CA Koetzner, CA Allen, SA Jones, H Chen, NN Zhang, M Tian, F Gao, Q Lin, N Banavali, J Zhou, N Boles, M Xia, LD Kramer, CF Qin, H Li. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res 2017; 27(8): 1046–1064 https://doi.org/10.1038/cr.2017.88
pmid: 28685770
31
MN Patel, MD Halling-Brown, JE Tym, P Workman, B Al-Lazikani. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 2013; 12(1): 35–50 https://doi.org/10.1038/nrd3913
pmid: 23274470
32
F Napolitano, Y Zhao, VM Moreira, R Tagliaferri, J Kere, M D’Amato, D Greco. Drug repositioning: a machine-learning approach through data integration. J Cheminform 2013; 5(1): 30 https://doi.org/10.1186/1758-2946-5-30
pmid: 23800010
33
A Pujol, R Mosca, J Farrés, P Aloy. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 2010; 31(3): 115–123 https://doi.org/10.1016/j.tips.2009.11.006
pmid: 20117850
34
KM Bullard-Feibelman, J Govero, Z Zhu, V Salazar, M Veselinovic, MS Diamond, BJ Geiss. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res 2017; 137: 134–140 https://doi.org/10.1016/j.antiviral.2016.11.023
pmid: 27902933
35
PK Mehrotra, S Kitchlu, A Dwivedi, PK Agnihotri, S Srivastava, R Roy, AP Bhaduri. Emetine ditartrate: a possible lead for emergency contraception. Contraception 2004; 69(5): 379–387 https://doi.org/10.1016/j.contraception.2003.12.011
pmid: 15105060
HK Bhatia, H Singh, N Grewal, NK Natt. Sofosbuvir: a novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother 2014; 5(4): 278–284 https://doi.org/10.4103/0976-500X.142464
pmid: 25422576
39
E Murakami, T Tolstykh, H Bao, C Niu, HM Steuer, D Bao, W Chang, C Espiritu, S Bansal, AM Lam, MJ Otto, MJ Sofia, PA Furman. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010; 285(45): 34337–34347 https://doi.org/10.1074/jbc.M110.161802
pmid: 20801890
40
DA Herbst Jr, KR Reddy. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 2013; 22(4): 527–536 https://doi.org/10.1517/13543784.2013.775246
pmid: 23448131
41
J Liu, J Du, P Wang, D Nagarathnam, CL Espiritu, H Bao, E Murakami, PA Furman, MJA Sofia. A 2′-deoxy-2′-fluoro-2′-C-methyl uridine cyclopentyl carbocyclic analog and its phosphoramidate prodrug as inhibitors of HCV NS5B polymerase. Nucleosides Nucleotides Nucleic Acids 2012; 31(4): 277–285 https://doi.org/10.1080/15257770.2012.658131
pmid: 22444190
42
N Mumtaz, LC Jimmerson, LR Bushman, JJ Kiser, G Aron, CBEM Reusken, MPG Koopmans, JJA van Kampen. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antiviral Res 2017; 146: 161–163 https://doi.org/10.1016/j.antiviral.2017.09.004
pmid: 28912011
43
HT Xu, SA Hassounah, SP Colby-Germinario, M Oliveira, C Fogarty, Y Quan, Y Han, O Golubkov, I Ibanescu, B Brenner, BR Stranix, MA Wainberg. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. J Antimicrob Chemother 2017; 72(3): 727–734 https://doi.org/10.1093/jac/dkw514
pmid: 28069884
44
H Matthews, M Usman-Idris, F Khan, M Read, N Nirmalan. Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malar J 2013; 12(1): 359 https://doi.org/10.1186/1475-2875-12-359
pmid: 24107123
45
S Krstin, T Mohamed, X Wang, M Wink. How do the alkaloids emetine and homoharringtonine kill trypanosomes? An insight into their molecular modes of action. Phytomedicine 2016; 23(14): 1771–1777 https://doi.org/10.1016/j.phymed.2016.10.008
pmid: 27912879
46
M Saif. Treatment of amoebiasis. J Egypt Public Health Assoc 1973; 48(3): 159–166
pmid: 4760109
47
S Yang, M Xu, EM Lee, K Gorshkov, SA Shiryaev, S He, W Sun, YS Cheng, X Hu, AM Tharappel, B Lu, A Pinto, C Farhy, CT Huang, Z Zhang, W Zhu, Y Wu, Y Zhou, G Song, H Zhu, K Shamim, C Martínez-Romero, A García-Sastre, RA Preston, DT Jayaweera, R Huang, W Huang, M Xia, A Simeonov, G Ming, X Qiu, AV Terskikh, H Tang, H Song, W Zheng. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov 2018; 4(1): 31 https://doi.org/10.1038/s41421-018-0034-1
pmid: 29872540
48
Y Lin, H Zhang, W Song, S Si, Y Han, J Jiang. Identification and characterization of Zika virus NS5 RNA-dependent RNA polymerase inhibitors. Int J Antimicrob Agents 2019; 54(4): 502–506 https://doi.org/10.1016/j.ijantimicag.2019.07.010
pmid: 31310806
49
S Helms, A Miller. Natural treatment of chronic rhinosinusitis. Altern Med Rev 2006; 11(3): 196–207
pmid: 17217321
50
JG Julander, V Siddharthan, J Evans, R Taylor, K Tolbert, C Apuli, J Stewart, P Collins, M Gebre, S Neilson, A Van Wettere, YM Lee, WP Sheridan, JD Morrey, YS Babu. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res 2017; 137: 14–22 https://doi.org/10.1016/j.antiviral.2016.11.003
pmid: 27838352
51
A Munjal, R Khandia, K Dhama, S Sachan, K Karthik, R Tiwari, YS Malik, D Kumar, RK Singh, HMN Iqbal, SK Joshi. Advances in developing therapies to combat Zika virus: current knowledge and future perspectives. Front Microbiol 2017; 8: 1469 https://doi.org/10.3389/fmicb.2017.01469
pmid: 28824594
52
A Kumar, B Liang, M Aarthy, SK Singh, N Garg, IU Mysorekar, R Giri. Hydroxychloroquine inhibits Zika virus NS2B-NS3 protease. ACS Omega 2018; 3(12): 18132–18141 https://doi.org/10.1021/acsomega.8b01002
pmid: 30613818
53
CL Murray, CT Jones, CM Rice. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat Rev Microbiol 2008; 6(9): 699–708 https://doi.org/10.1038/nrmicro1928
pmid: 18587411
54
P Erbel, N Schiering, A D’Arcy, M Renatus, M Kroemer, SP Lim, Z Yin, TH Keller, SG Vasudevan, U Hommel. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 2006; 13(4): 372–373 https://doi.org/10.1038/nsmb1073
pmid: 16532006
Z Li, M Brecher, YQ Deng, J Zhang, S Sakamuru, B Liu, R Huang, CA Koetzner, CA Allen, SA Jones, H Chen, NN Zhang, M Tian, F Gao, Q Lin, N Banavali, J Zhou, N Boles, M Xia, LD Kramer, CF Qin, H Li. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res 2017; 27(8): 1046–1064 https://doi.org/10.1038/cr.2017.88
pmid: 28685770
57
I Yakavets, HP Lassalle, D Scheglmann, A Wiehe, V Zorin, L Bezdetnaya. Temoporfin-in-cyclodextrin-in-liposome—a new approach for anticancer drug delivery: the optimization of composition. Nanomaterials (Basel) 2018; 8(10): E847 https://doi.org/10.3390/nano8100847
pmid: 30340318
Z Shi, J Wei, X Deng, S Li, Y Qiu, D Shao, B Li, K Zhang, F Xue, X Wang, Z Ma. Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol J 2014; 11(1): 10 https://doi.org/10.1186/1743-422X-11-10
pmid: 24456815
60
OH Rizk, MG Bekhit, AAB Hazzaa, EM El-Khawass, IA Abdelwahab. Synthesis, antibacterial evaluation, and DNA gyrase inhibition profile of some new quinoline hybrids. Arch Pharm (Weinheim) 2019; 352(10): e1900086 https://doi.org/10.1002/ardp.201900086
pmid: 31389630
61
S Yuan, JF Chan, H den-Haan, KK Chik, AJ Zhang, CC Chan, VK Poon, CC Yip, WW Mak, Z Zhu, Z Zou, KM Tee, JP Cai, KH Chan, J de la Peña, H Pérez-Sánchez, JP Cerón-Carrasco, KY Yuen. Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection invitro and invivo. Antiviral Res 2017; 145: 33–43 https://doi.org/10.1016/j.antiviral.2017.07.007
pmid: 28712942
62
RH Flatman, A Eustaquio, SM Li, L Heide, A Maxwell. Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis. Antimicrob Agents Chemother 2006; 50(4): 1136–1142 https://doi.org/10.1128/AAC.50.4.1136-1142.2006
pmid: 16569821
63
JF Chan, KK Chik, S Yuan, CC Yip, Z Zhu, KM Tee, JO Tsang, CC Chan, VK Poon, G Lu, AJ Zhang, KK Lai, KH Chan, RY Kao, KY Yuen. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antiviral Res 2017; 141: 29–37 https://doi.org/10.1016/j.antiviral.2017.02.002
pmid: 28185815
64
OJ Ginther, VG Santos, RA Mir, MA Beg. Role of LH in the progesterone increase during the bromocriptine-induced prolactin decrease in heifers. Theriogenology 2012; 78(9): 1969–1976 https://doi.org/10.1016/j.theriogenology.2012.08.003
pmid: 23110952
65
Y Li, Z Zhang, WW Phoo, YR Loh, R Li, HY Yang, AE Jansson, J Hill, TH Keller, K Nacro, D Luo, C Kang. Structural insights into the inhibition of Zika virus NS2B-NS3 protease by a small-molecule inhibitor. Structure 2018; 26(4): 555–564.e3 https://doi.org/10.1016/j.str.2018.02.005
pmid: 29526431
66
Y Geng, L Kohli, BJ Klocke, KA Roth. Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 2010; 12(5): 473–481
pmid: 20406898
67
X Zhu, Y Pan, Y Li, Y Jiang, H Shang, DC Gowda, L Cui, Y Cao. Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria. Int Immunopharmacol 2012; 13(4): 392–397 https://doi.org/10.1016/j.intimp.2012.05.012
pmid: 22659438
68
DJ Browning. Pharmacology of chloroquine and hydroxychloroquine. In: Hydroxychloroquine and Chloroquine Retinopathy. New York: Springer, 2014: 35–63 https://doi.org/10.1007/978-1-4939-0597-3_2
69
WP Tsai, PL Nara, HF Kung, S Oroszlan. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990; 6(4): 481–489 https://doi.org/10.1089/aid.1990.6.481
pmid: 1692728
70
KJ Farias, PR Machado, BA da Fonseca. Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells. ScientificWorldJournal 2013; 2013: 282734 https://doi.org/10.1155/2013/282734
pmid: 23431254
71
YZ Zhu, QQ Xu, DG Wu, H Ren, P Zhao, WG Lao, Y Wang, QY Tao, XJ Qian, YH Wei, MM Cao, ZT Qi. Japanese encephalitis virus enters rat neuroblastoma cells via a pH-dependent, dynamin and caveola-mediated endocytosis pathway. J Virol 2012; 86(24): 13407–13422 https://doi.org/10.1128/JVI.00903-12
pmid: 23015720
72
EE Ooi, JS Chew, JP Loh, RC Chua. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 2006; 3(1): 39 https://doi.org/10.1186/1743-422X-3-39
pmid: 16729896
73
Y Zhu, Y Lin, X Liu, W Hu, Y Wang. Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition. Biochem Biophys Res Commun 2017; 483(1): 495–501 https://doi.org/10.1016/j.bbrc.2016.12.116
pmid: 28007598
74
SA Shiryaev, P Mesci, A Pinto, I Fernandes, N Sheets, S Shresta, C Farhy, CT Huang, AY Strongin, AR Muotri, AV Terskikh. Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep 2017; 7(1): 15771 https://doi.org/10.1038/s41598-017-15467-6
pmid: 29150641
75
Y Han, T Mesplède, H Xu, Y Quan, MA Wainberg. The antimalarial drug amodiaquine possesses anti-Zika virus activities. J Med Virol 2018; 90(5): 796–802 https://doi.org/10.1002/jmv.25031
pmid: 29315671
76
I Law, KF Ilett, LP Hackett, M Page-Sharp, F Baiwog, S Gomorrai, I Mueller, HA Karunajeewa, TM Davis. Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers. Br J Clin Pharmacol 2008; 65(5): 674–679 https://doi.org/10.1111/j.1365-2125.2008.03111.x
pmid: 18279478
I Ben-Zvi, S Kivity, P Langevitz, Y Shoenfeld. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012; 42(2): 145–153 https://doi.org/10.1007/s12016-010-8243-x
pmid: 21221847
80
RW Berliner, DP Earle Jr, JV Taggart, CG Zubrod, WJ Welch, NJ Conan, E Bauman, ST Scudder, JA Shannon. Studies on the chemotherapy of the human malarias; of the human malarias the physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest 1948; 27(3): 98–107 https://doi.org/10.1172/JCI101980
pmid: 18860187
81
R Tzekov. Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. Doc Ophthalmol 2005; 110(1): 111–120 https://doi.org/10.1007/s10633-005-7349-6
pmid: 16249962
PM O’Neill, PG Bray, SR Hawley, SA Ward, BK Park. 4-Aminoquinolines—past, present, and future: a chemical perspective. Pharmacol Ther 1998; 77(1): 29–58 https://doi.org/10.1016/S0163-7258(97)00084-3
pmid: 9500158
84
JM Rolain, P Colson, D Raoult. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007; 30(4): 297–308 https://doi.org/10.1016/j.ijantimicag.2007.05.015
pmid: 17629679
85
B Cao, LA Parnell, MS Diamond, IU Mysorekar. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med 2017; 214(8): 2303–2313 https://doi.org/10.1084/jem.20170957
pmid: 28694387
86
YC Kaplan, J Ozsarfati, C Nickel, G Koren. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol 2016; 81(5): 835–848 https://doi.org/10.1111/bcp.12872
pmid: 26700396
87
S Pukrittayakamee, M Imwong, S Looareesuwan, NJ White. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop 2004; 89(3): 351–356 https://doi.org/10.1016/j.actatropica.2003.10.012
pmid: 14744561
88
KJ Palmer, SM Holliday, RN Brogden. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45(3): 430–475 https://doi.org/10.2165/00003495-199345030-00009
pmid: 7682911
89
Y Liu, S Chen, R Xue, J Zhao, M Di. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway. Biochem Biophys Res Commun 2016; 470(2): 350–355 https://doi.org/10.1016/j.bbrc.2016.01.046
pmid: 26780727
90
D Krieger, S Vesenbeckh, N Schönfeld, G Bettermann, TT Bauer, H Rüssmann, H Mauch. Mefloquine as a potential drug against multidrug-resistant tuberculosis. Eur Respir J 2015; 46(5): 1503–1505 https://doi.org/10.1183/13993003.00321-2015
pmid: 26206875
91
M Brickelmaier, A Lugovskoy, R Kartikeyan, MM Reviriego-Mendoza, N Allaire, K Simon, RJ Frisque, L Gorelik. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53(5): 1840–1849 https://doi.org/10.1128/AAC.01614-08
pmid: 19258267
92
G Barbosa-Lima, AM Moraes, ADS Araújo, ET da Silva, CS de Freitas, YR Vieira, A Marttorelli, JC Neto, PT Bozza, MVN de Souza, TML Souza. 2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine. Eur J Med Chem 2017; 127: 334–340 https://doi.org/10.1016/j.ejmech.2016.12.058
pmid: 28068604
93
S Qiao, S Tao, M Rojo de la Vega, SL Park, AA Vonderfecht, SL Jacobs, DD Zhang, GT Wondrak. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. Autophagy 2013; 9(12): 2087–2102 https://doi.org/10.4161/auto.26506
pmid: 24113242
94
T Zhou, L Tan, GY Cederquist, Y Fan, BJ Hartley, S Mukherjee, M Tomishima, KJ Brennand, Q Zhang, RE Schwartz, T Evans, L Studer, S Chen. High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus infection in fetal-like organoids and adult brain. Cell Stem Cell 2017; 21(2): 274–283.e5 https://doi.org/10.1016/j.stem.2017.06.017
pmid: 28736217
95
L Zilbermintz, W Leonardi, SY Jeong, M Sjodt, R McComb, CL Ho, C Retterer, D Gharaibeh, R Zamani, V Soloveva, S Bavari, A Levitin, J West, KA Bradley, RT Clubb, SN Cohen, V Gupta, M Martchenko. Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. Sci Rep 2015; 5(1): 13476 https://doi.org/10.1038/srep13476
pmid: 26310922
96
AR Parhizgar, A Tahghighi. Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iran J Med Sci 2017; 42(2): 115–128
pmid: 28360437
97
M Sarkar, C Woodland, G Koren, AR Einarson. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006; 6(1): 18 https://doi.org/10.1186/1471-2393-6-18
pmid: 16734900
98
H Retallack, E Di Lullo, C Arias, KA Knopp, MT Laurie, C Sandoval-Espinosa, WR Mancia Leon, R Krencik, EM Ullian, J Spatazza, AA Pollen, C Mandel-Brehm, TJ Nowakowski, AR Kriegstein, JL DeRisi. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA 2016; 113(50): 14408–14413 https://doi.org/10.1073/pnas.1618029113
pmid: 27911847
99
PS Ramsey, MB Vaules, GM Vasdev, WW Andrews, KD Ramin. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol 2003; 188(3): 714–718 https://doi.org/10.1067/mob.2003.141
pmid: 12634646
100
MW Kemp, Y Miura, MS Payne, AH Jobe, SG Kallapur, M Saito, SJ Stock, OB Spiller, DJ Ireland, N Yaegashi, M Clarke, D Hahne, J Rodger, JA Keelan, JP Newnham. Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy. Antimicrob Agents Chemother 2014; 58(11): 6581–6591 https://doi.org/10.1128/AAC.03721-14
pmid: 25155606
BI Eisenstein. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs 2004; 13(9): 1159–1169 https://doi.org/10.1517/13543784.13.9.1159
pmid: 15330747
103
DM Shoemaker, J Simou, WE Roland. A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections. Ther Clin Risk Manag 2006; 2(2): 169–174 https://doi.org/10.2147/tcrm.2006.2.2.169
pmid: 18360590
104
M Dei Cas, E Casagni, V Gambaro, E Cesari, G Roda. Determination of daptomycin in human plasma and breast milk by UPLC/MS-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1116: 38–43 https://doi.org/10.1016/j.jchromb.2019.03.036
pmid: 30953921
105
M McCall, C Toso, J Emamaullee, R Pawlick, R Edgar, J Davis, A Maciver, T Kin, R Arch, AM Shapiro. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery 2011; 150(1): 48–55 https://doi.org/10.1016/j.surg.2011.02.023
pmid: 21596412
106
JJ Haddad. Current opinion on 3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid, an investigational drug targeting caspases and caspase-like proteases: the clinical trials in sight and recent anti-inflammatory advances. Recent Pat Inflamm Allergy Drug Discov 2013; 7(3): 229–258 https://doi.org/10.2174/1872213X113079990017
pmid: 23859695
107
NC Hoglen, LS Chen, CD Fisher, BP Hirakawa, T Groessl, PC Contreras. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther 2004; 309(2): 634–640 https://doi.org/10.1124/jpet.103.062034
pmid: 14742742
108
FJ Barreyro, S Holod, PV Finocchietto, AM Camino, JB Aquino, A Avagnina, MC Carreras, JJ Poderoso, GJ Gores. The pan-caspase inhibitor emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int 2015; 35(3): 953–966 https://doi.org/10.1111/liv.12570
pmid: 24750664
109
ML Shiffman, P Pockros, JG McHutchison, ER Schiff, M Morris, G Burgess. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor — a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010; 31(9): 969–978 https://doi.org/10.1111/j.1365-2036.2010.04264.x
pmid: 20163376
110
BO Duke. The effects of drugs on Onchocerca volvulus. 3. Trials of suramin at different dosages and a comparison of the brands Antrypol, Moranyl and Naganol. Bull World Health Organ 1968; 39(2): 157–167
pmid: 4881068
111
IC Albulescu, K Kovacikova, A Tas, EJ Snijder, MJ van Hemert. Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles. Antiviral Res 2017; 143: 230–236 https://doi.org/10.1016/j.antiviral.2017.04.016
pmid: 28461070